Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calibrant Biosystems has signed a cooperative R&D agreement with the Armed Forces Institute of Pathology to explore the use of the company's Gemini proteomics technology in the discovery and development of novel protein biomarkers.
Subscribe to our email newsletter
Under the cooperative R&D agreement, the collaboration will leverage Calibrant’s unique proteomic technologies for the purposes of evaluating and validating protein markers for a variety of major, unmet medical needs.
Armed Forces Institute of Pathology’s (AFIP) tissue microarray laboratory will produce standard and custom tissue microarrays in agreement with Calibrant’s specifications. The initial project will be in the area of brain cancer, with the ultimate goal of identifying predictive markers for personalized medicine.
Michael Salgaller, COO of Calibrant, said: “Working in partnership with the AFIP via this cooperative R&D agreement, offers an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples.”